Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in Patients with Cancer
Passive immunisation with tixagevimab and cilgavimab may not be effective
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Passive immunisation with tixagevimab and cilgavimab may not be effective
From the World Conference on Lung Cancer 2022:
Around a fifth of patients with thoracic cancer die within 30 days of COVID-19 infection but the risk is not predicted by recent receipt of systematic treatment for their malignancy
Very suboptimal vaccine responses generated by subset of patients with non-small cell lung cancer cannot be explained solely by older age and type of vaccine
Patients with cancer, especially haematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
Most patients were on active anticancer treatment during the 28 days before the administration of third dose
Findings from the COVID-19 and Cancer Consortium cohort study
The rate of negative antibody results highest among patients with lymphoid neoplasms
Updated results of the Vax-On study favour the third vaccine dose for actively treated patients with cancer
Patients with cancer who survive COVID-19 may develop long-term sequelae that can disrupt oncological treatment and shorten survival
Third vaccine dose could be immunologically beneficial for patients on active chemotherapy
Findings from the largest study to measure anti-SARS-CoV-2 antibody levels after vaccination in patients with haematological and solid malignant tumours
From the ESMO Congress 2021:
The CAPTURE study has characterised functional immune responses in people with cancer following SARS-CoV-2 infection or vaccination
Findings from the Vax-On study show a favourable safety profile of mRNA-based COVID-19 vaccine in patients with solid tumours during active anticancer treatment
From the ESMO Congress 2021:
Most solid tumour patients recently given chemotherapy and/or immunotherapy will achieve an adequate antibody response to COVID-19 vaccination
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
A global hospital-based registry sheds light on the outcomes of children and adolescents with cancer and COVID-19
The seroconversion rate in response to full vaccination against SARS-CoV-2 was low in a single-centre study of adults with haematological malignancies
Findings from an analysis of the clinical efficacy of COVID-19 vaccination in a large series of patients with cancer
Axillary adenopathy may be present in women who undergo mammography within 90 days of COVID-19 vaccination
No seroconversion found upon a single dose in elderly cancer patients and those treated with chemotherapy, a reason for not extending the period between the two injections
Cancer patients should be given their second dose of the BNT162b2 vaccine 21 days after their first to ensure protection from SARS-CoV-2 infection
The BNT162b2 mRNA vaccine has a similar profile of short-term side effects for cancer patients undergoing immune checkpoint inhibitor therapy and healthy individuals
Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines
More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates
A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia
Findings from the COVID-19 and Cancer Consortium
Results from a cross-sectional survey in France
Use of radiotherapy changed significantly in England during the first COVID-19 wave
Use of systemic treatments by cancer patients in England fell in April 2020 but surged in June 2020
Dutch registry findings describe the effect of the SARS-CoV-2 pandemic on cancer patients and the general population
Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk
IgG antibody response to SARS-CoV-2 infection may be comparable among cancer patients and healthy oncology healthcare workers
Interim results of the SAKK 80/20 CaSA study suggest around 18% of Swiss cancer patients with SARS-CoV-2 infection have died
Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals
Literature analysis suggests that approximately 25% of cancer patients with COVID-19 have died
Low SARS-CoV-2 seroprevalence in both, oncology healthcare workers and cancer patients require continuation of strict safety measures
ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.
UK data suggest the risk of acquiring COVID-19 and the severity of infection differ by the type of cancer
Findings from a systematic review and meta-analysis
Haematological malignancy patients with COVID-19 may have a high mortality rate
Findings from a large regional analysis of population that examined the prevalence of cancer and clinical outcomes of viral infection
Findings from a large testing study conducted at a tertiary care hospital in Vienna
An experience of the Drug Development Department of the Gustave Roussy
Restrictive measures to control the spread of COVID-19 have adverse effect on continuation of radiotherapy in patients with cancer
In Annals of Oncology, ESMO’s comprehensive set of recommendations address open questions on how to manage cancer care in the COVID-19 era
Modelling studies predict the outcome of COVID-19 pandemic-related cancer diagnostic delays in England
An interim analysis of survey data in the context of the COVID-19 pandemic
Data from prostate cancer patients in Italy and Finland do not support the hypothesis that androgen deprivation therapy may reduce the risk of SARS-CoV-2 infection
Results from the survey among 5302 cancer patients in the Netherlands
A delay in cancer surgery because of the COVID-19 pandemic may have a significant impact on patient survival
An immunocompromised cancer patient with bone marrow positive for SARS-CoV-2 has developed pancytopenia
A study of cancer patients attending a New York hospital details the rates of hospitalisation, morbidity and mortality associated with COVID-19
Around 10% of cancer patients with suspected or confirmed COVID-19 die within 25 days of being admitted to hospital with symptoms
A study of cancer patients with COVID-19 has identified several risk factors for mortality
More safety data is needed in terms of treatment of symptomatic COVID-19 patients with anticancer drugs
Findings from the MSKCC series
Findings from two Chinese multicentre, retrospective, cohort studies
Results of the UK Coronavirus Cancer Monitoring Project
The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection
Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality
Multifactorial reasons involving patients, general practitioners and the healthcare system
Prostate cancer patients using androgen deprivation therapy might have a lower risk of SARS-CoV-2 infection than other cancer patients
Antibodies more often undetectable in patients who received anticancer treatment in the month prior to testing
Balancing pandemic control with providing continued cancer care
Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group
Treatment delay of at least 2 months reported in only one quarter of patients
An experience in New York City
Research priorities related to incidence, morbidity and mortality of COVID-19 specific to patients with cancer
An accurate COVID-19 screening model could allow early detection and potentially reduce the risk of severe complications and mortality
Patients with cancer and cancer survivors may have a higher risk of COVID-19 than the general population
A metastatic renal cell carcinoma patient who developed COVID-19 may have benefited from treatment with an IL-6 receptor inhibitor
Guidelines commissioned by the French health authorities
Actions taken at a Chinese cancer hospital may have prevented the spread of SARS-CoV-2 and COVID-19
Situation in the first half of March 2020
Analysis of risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or death
Open access: Early data on the transmission of SARS-CoV-2 in Wuhan cancer patients have been published
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.